Naya Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
INVO Fertility, Inc. filed an amendment to its 2025 Annual Report to provide required Part III proxy information and updated certifications.
INVO Fertility, Inc. outlines its authorized capital stock, including common and various series of preferred stock, detailing their rights and conversion terms.
INVO Fertility files an amendment to its 2024 annual report on Form 10-K to include its Clawback Policy and related disclosures regarding executive compensation recovery.
INVO Fertility, formerly NAYA Biosciences, will refocus on its fertility business and divest its NAYA Therapeutics subsidiary after failing to gain shareholder support for key transaction elements.
10-K/A: NAYA Biosciences Restates Financials Due to Lease Accounting Error, Reports Full Year 2023 Results
NAYA Biosciences restated its financial statements for multiple periods due to an error in calculating lease discount rates, while also reporting its full year 2023 results including a significant increase in clinic revenue and a net loss.
10-K/A: INVO Bioscience Files Amended 10-K Report, Addresses Executive Compensation and Merger Details
INVO Bioscience has filed an amendment to its annual report on Form 10-K, primarily to include information required by Part III of the form and updated certifications, while also detailing executive compensation, board composition, and the proposed merger with NAYA Biosciences.
INVO Bioscience has filed an amendment to its annual report to include an updated auditor consent and a change to the useful life of non-competition agreements.
INVO Bioscience's 2023 annual report details a strategic shift towards clinic-based operations, including the acquisition of Wisconsin Fertility Institute, and a pending merger with NAYA Biosciences.
INVO Bioscience has filed an amendment to its annual report to include an updated consent from its independent auditor and certifications from its principal executive and financial officers.